| Detection of circulating tumor DNA in early-and late-stage human malignancies C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ... Science translational medicine 6 (224), 224ra24-224ra24, 2014 | 4761 | 2014 |
| AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ... New England Journal of Medicine 371 (11), 1028-1038, 2014 | 2830 | 2014 |
| Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ... Journal of Clinical Oncology 34 (12), 1402-1418, 2016 | 1342 | 2016 |
| Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology JL Mohler, ES Antonarakis, AJ Armstrong, AV D’Amico, BJ Davis, T Dorff, ... Journal of the National Comprehensive Cancer Network 17 (5), 479-505, 2019 | 1245 | 2019 |
| Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial R Phillips, WY Shi, M Deek, N Radwan, SJ Lim, ES Antonarakis, SP Rowe, ... JAMA oncology 6 (5), 650-659, 2020 | 864 | 2020 |
| Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, M Nakazawa, R Nadal, ... JAMA oncology 1 (5), 582-591, 2015 | 687 | 2015 |
| Ruthenium-based chemotherapeutics: are they ready for prime time? ES Antonarakis, A Emadi Cancer chemotherapy and pharmacology 66, 1-9, 2010 | 640 | 2010 |
| Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study ES Antonarakis, JM Piulats, M Gross-Goupil, J Goh, K Ojamaa, ... Journal of Clinical Oncology 38 (5), 395-405, 2020 | 570 | 2020 |
| Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer Z Szabo, E Mena, SP Rowe, D Plyku, R Nidal, MA Eisenberger, ... Molecular imaging and biology 17, 565-574, 2015 | 492 | 2015 |
| Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with … ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, Y Zhu, JL Silberstein, ... Journal of Clinical Oncology 35 (19), 2149-2156, 2017 | 444 | 2017 |
| Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology P Nuhn, JS De Bono, K Fizazi, SJ Freedland, M Grilli, PW Kantoff, ... European urology 75 (1), 88-99, 2019 | 416 | 2019 |
| TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? KH Stopsack, LA Mucci, ES Antonarakis, PS Nelson, PW Kantoff Cancer discovery 10 (6), 779-782, 2020 | 386 | 2020 |
| NCCN guidelines insights: Prostate cancer, version 1.2021: Featured updates to the NCCN guidelines E Schaeffer, S Srinivas, ES Antonarakis, AJ Armstrong, JE Bekelman, ... Journal of the National Comprehensive Cancer Network 19 (2), 134-143, 2021 | 354 | 2021 |
| Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study AJ Armstrong, S Halabi, J Luo, DM Nanus, P Giannakakou, ... Journal of Clinical Oncology 37 (13), 1120-1129, 2019 | 312 | 2019 |
| The natural history of metastatic progression in men with prostate‐specific antigen recurrence after radical prostatectomy: long‐term follow‐up ES Antonarakis, Z Feng, BJ Trock, EB Humphreys, MA Carducci, ... BJU international 109 (1), 32-39, 2012 | 312 | 2012 |
| Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer CJ Paller, ES Antonarakis Drug design, development and therapy, 117-124, 2011 | 310 | 2011 |
| PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer SP Rowe, KJ Macura, E Mena, AL Blackford, R Nadal, ES Antonarakis, ... Molecular imaging and biology 18, 411-419, 2016 | 263 | 2016 |
| Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study MT Schweizer, ES Antonarakis, H Wang, AS Ajiboye, A Spitz, H Cao, ... Science translational medicine 7 (269), 269ra2-269ra2, 2015 | 259 | 2015 |
| Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions CJ Paller, ES Antonarakis Clinical advances in hematology & oncology: H&O 11 (1), 14, 2013 | 237 | 2013 |
| Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012 M Hussain, S Daignault-Newton, PW Twardowski, C Albany, MN Stein, ... Journal of Clinical Oncology 36 (10), 991-999, 2018 | 213 | 2018 |
Mario EisenbergerProfessor of Oncology,Johns Hopkins University在 jhmi.edu 的电子邮件经过验证
